Overview

A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to investigate the efficacy and safety of HIPEC plus apatinib and S-1 in the conversion therapy of gastric cancer with positive exfoliative cancer cells
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hebei Medical University
Treatments:
Albumin-Bound Paclitaxel
Apatinib
Paclitaxel
Criteria
Inclusion Criteria:

- 1. Untreated (e.g. chemotherapy, radiotherapy and other antitumor therapy); 2. Age:18
to 70 years old; 3. Man or female (except pregnant and lactating women); 4. Confirmed
to gastric adenocarcinoma; 5. Proven gastric cancer of T stage was T3 and T4, and no
distant metastasis was observed. The exfoliative cancer cells detection in peritoneal
washes was positive; 6. Blood cell count has to meet the following certeria:
WBC≥3.5×109/L; ANC≥1.5×109/L; PLT≥100×109/L; HB≥90g/L; 7. Liver/kidney function has to
meet the following certeria: ALT and AST≤2.5×ULN TBIL<1.5×ULN； Serum creatinine
≤1.5×ULN; 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 9.
Participants were willing to join in this study, good adherence and written informed
consent.

Exclusion Criteria:

- 1. Patients with other malignant tumors within 5 years; 2. Metastasis was found to be
visible to the naked eye; 3. It has serious or uncontrolled heart diseases and infections
(Including atrial fibrillation, angina pectoris, cardiac insufficiency, ejection fraction
less than 50%, poor-controlled hypertension and so on); 4. History of psychiatric drugs
abuse and can't quit or patients with mental disorders; 5. Patients with severe or
uncontrollable mental illness; 6. Patients with tendency of gastrointestinal bleeding,
including the following: a local active ulcerative lesions, and defecate occult blood (+
+).Has melena and hematemesis in two months; 7. Pregnant or lactating women; 8. It have
serious harm to the patient's safety or affect the patients who have completed the
research.

9. The researchers think inappropriate.